ERSP gives Swiss Labs go-ahead with changes
This article was originally published in The Tan Sheet
Executive SummaryThe Electronic Retailing Self-Regulation Program gives thumbs up to Swiss Labs for substantiating most claims for its Arthi-Zen Relief Dietary Supplement, but asks the firm to modify certain statements. ERSP says July 9 the marketer's clinical study supported general efficacy claims for the reduction of joint and muscle discomfort, but asks the firm to remove mention of "clinical studies" because there is only one. The group also asked Swiss Labs to modify the "immediate" relief claim because the study suggested most saw improvement after four days, and to modify the context of the claim "24-Hour Joint Relief" to explain that users "can experience relief for up to 24 hours in between dosages." Swiss Labs said it will comply. ERSP reviewed the Kankakee, Ill.-based firm's ads in ongoing monitoring
You may also be interested in...
Grail announced it will enroll about 6,200 people in an interventional, multi-center study evaluating its multi-cancer early-detection blood test. This is the first time health care providers will use this test to help guide patient care.
As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.